The DERM AI system has boosted patient intake at St. Luke's Hospital by 30%, enhancing efficiency and reducing unnecessary procedures.
St. Luke's Hospital in Bradford, UK, has successfully increased its patient intake by 30% through the introduction of the DERM AI system, allowing the clinic to assist 32 patients in each session compared to 24 previously. This advancement has also led to a reduction in unnecessary biopsies by approximately 10%, as reported by BBC.
The DERM algorithm, created by British company Skin Analytics, evaluates images of suspicious skin lesions to determine the risk of cancer. Medical staff use a smartphone with a dermatoscope attachment to capture images of potentially problematic moles, and the system swiftly analyzes them within minutes.
Patients identified with benign conditions receive care recommendations, while those with potential cancer indications are immediately referred to specialists. Every diagnosis generated by DERM is subsequently confirmed by hospital physicians.
“This has significantly affected all bottlenecks — from patient wait times to unnecessary tests and appointment delays,” said Zakir Sharif, plastic surgeon and clinical lead for skin cancer.
Since its launch on April 30, DERM has made St. Luke's Hospital the first NHS trust in West Yorkshire to implement this technology, which is now utilized across 40 organizations. The trust reports handling around 5,000 skin cancer referrals annually, with only about 8% resulting in a malignant diagnosis.
Assessing DERM's Performance
Skin Analytics asserts that DERM has a remarkable negative predictive value (NPV) of 99.9% for melanoma, indicating its high reliability in correctly identifying non-melanoma cases. The system's overall sensitivity for all skin cancer types stands at 98%, based on post-marketing surveillance data.
An independent review for the AI in Health and Care Award program found a sensitivity of 97% specifically for melanoma cases. Another NHS England study involving 33,700 cases noted an NPV of 99.8% for melanoma diagnosed by DERM, compared to 98.9% for dermatologists during personal consultations.
The National Institute for Health and Care Excellence has recommended DERM for conditional use in the NHS for a three-year period to further assess its clinical and economic impact.
Additionally, a new AI blood test, PinPoint, is set to be used by two NHS trusts for detecting uterine cancer, having demonstrated a 99% accuracy rate among 3,313 participants for identifying and ruling out gynecological cancers.